Navigation Links
Herborium Announces Continuing Progress In Key Strategic Initiatives
Date:5/4/2012

TEANECK, N.J., May 4, 2012 /PRNewswire/ -- Herborium Group, Inc., (PINKS. HBRM) www.herborium.com, a Botanical Therapeutics® company, reports today continuing progress with its key strategic initiatives.

The company is progressing through the negotiating phase with China Health Resource Inc. regarding a potential acquisition. Both, Herborium Group and China Resource continue to work diligently towards a successful transaction.      

Herborium's partnership with KAMASUTRA (USA), LLC  to commercialize their unique vodka product containing Herborium's proprietary herbal formula  derived from the Company's sexual health formulations, has moved into the introductory marketing phase with the digital marketing plan to be initiated in June 2012.  Market share for vodka in the US is $4.8 Billion in annual sales with both on premise and home consumption on the rise.  KAMASUTRA (USA) LLC is the US partner of the German Bismarck Premium Brands GmbH  www.bismarck.de  and http://www.bismarck.de/kamasutra/englisch/kamasutra_ginseng_vodka.html.

The market for pharmaceutical sexual health products is over $3.2 billion worldwide. The market for natural sexual health products is estimated to be over $1.5 billion, and growing.

Dr. Agnes P. Olszewski, CEO of Herborium, recently completed the National Publicity Summit in New York City (April 25-29, 2012). The Company is looking forward to multiple media exposure opportunities resulting from this Summit  that shall greatly elevate  Herborium's  public awareness.

About Herborium Group, Inc.

Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company uses clinical validation to establish and maintain a differential advantage. The company markets its products in the US and Europe. For more information, please visit www.herborium.com and www.acnease.com.

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

For more information please inquire: Investorsrelations@herborium.com


'/>"/>
SOURCE Herborium Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Herborium Group Shareholders Update
2. Bacterin Announces First Quarter 2012 Revenue of $7.8 Million, Up 29% Year-over-Year, on Gross Margins of 76%, and 34% Reduction in Operating Loss
3. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
4. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
5. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
6. Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India
7. Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device
8. Hill-Rom Announces Third Quarter 2012 Dividend
9. Trovagene Announces Plans to Develop Proprietary Test for High Risk HPV Carrier Screening from Urine
10. Medical Guardian Announces Social Media Partnership with Senior Citizen Charity
11. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
(Date:4/18/2017)...  Cardinal Health (NYSE: CAH ) today ... per share (EPS) guidance and providing a preliminary view ... with this morning,s announcement of the planned acquisition of ... businesses. Cardinal Health now believes that fiscal ... the bottom of its previous guidance range of $5.35 ...
(Date:4/18/2017)... 2017 Viverae ® , a leader in ... of IBM ® Watson Campaign Automation, implementing behavioral ... for a personalized experience. Through digital engagement, the platform ... in real time. The enhanced experience drives engagement by ... wherever they are in their journey to health. ...
Breaking Medicine Technology:
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of ... many times purer and more potent than the market has seen before. Swissx uses ... as well as a patented chromatography process for extraction, to produce its CBD oil--maximizing ...
(Date:4/26/2017)... ... April 26, 2017 , ... Intalere, the healthcare ... podcast, “Make Plans for MACRA,” highlighting the impact of the Medicare ... and how physicians and other clinicians are reimbursed for the care they deliver ...
(Date:4/26/2017)... Aviv, Israel (PRWEB) , ... April 26, 2017 , ... ... today announced a new partnership with Med-e-Mass , the largest Electronic Medical Records ... enable Med-e-Mass to link care plan incentives to a patient’s remote health progress, empowering ...
(Date:4/26/2017)... Miami, FL (PRWEB) , ... April 26, 2017 , ... ... twenty-fifth anniversary as a dentist. , “I could have never imagined back in 1991 ... and personally,” said Dr. Gallardo. , Over the last 25 years, Dr. Gallardo has ...
(Date:4/26/2017)... (PRWEB) , ... April 26, ... ... which provides an agile ecosystem and domain expertise for sponsors and CROs ... randomization and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
Breaking Medicine News(10 mins):